How will Immutep shares react after latest announcement?

Source:Khakimullin , Shutterstock

Summary

  • Immutep Ltd’s (ASX:IMM) lead product candidate eftilagimod alpha or efti has received fast track designation from the United States Food and Drug Administration (FDA).
  • Immutep develops novel immunotherapy treatments for cancer, infectious and autoimmune diseases.

Global biotechnology company Immutep Ltd (ASX:IMM) on Thursday announced that its lead product candidate eftilagimod alpha or efti had received fast track designation from the United States Food and Drug Administration (FDA).

Efti, a soluble LAG-3 protein, has received fast track designation in 1st line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Immutep develops novel immunotherapy treatments for cancer, infectious and autoimmune diseases.

Source: © Janeh 15 | Megapixl.com

What FDA evaluated

According to the company update released earlier on Thursday, the data package evaluated by the FDA included the promising results from Part C of Immutep’s Phase II TACTI-002 trial evaluating efti in combination with KEYTRUDA® (pembrolizumab) 2nd line PD-X naive HNSCC, and its plans for a trial in 1st line HNSCC (TACTI-003).

Interim clinical data from TACTI-002 was presented at the Society for Immunotherapy of Cancer (SITC) in November 2020. The Overall Response Rate (ORR) reported at SITC was approximately 36 per cent for 28 patients receiving efti in combination with KEYTRUDA.

On 16 March 2021, Immutep announced that it had entered in a second collaboration with MSD to evaluate efti in combination with KEYTRUDA in a new Phase IIb trial in 1st line HNSCC, TACTI-003. The company said that the planning for this trial was advancing well and the study is expected to start in mid-2021.

Source: © Lesserdesignen | Megapixl.com

READ MORE: These 10 ASX dividend stars deserve your attention!

Stock performance

Shares of Immutep closed at A$0.44, up 3.53 per cent on Wednesday, 7 April 2021, as against the previous closing on Tuesday, 6 April 2021. The stock has given a return of 4.5 per cent so far this year.

READ MORE: INR puts worst show in 20 months on fears of liquidity glut

 

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK